Results 281 to 290 of about 65,011 (307)
Some of the next articles are maybe not open access.
Journal of Veterinary Pharmacology and Therapeutics, 2012
The purpose of this study was to assess the clinical effects of dexmedetomidine, both alone and combined with pethidine or butorphanol, in cats. A prospective randomized blind study was performed. Thirty cats were randomly assigned to three groups of 10 animals: D: dexmedetomidine (20 μg/kg IM); DP: dexmedetomidine (10 μg/kg IM) and pethidine (2.5 mg ...
L. Gil +5 more
openaire +3 more sources
The purpose of this study was to assess the clinical effects of dexmedetomidine, both alone and combined with pethidine or butorphanol, in cats. A prospective randomized blind study was performed. Thirty cats were randomly assigned to three groups of 10 animals: D: dexmedetomidine (20 μg/kg IM); DP: dexmedetomidine (10 μg/kg IM) and pethidine (2.5 mg ...
L. Gil +5 more
openaire +3 more sources
Dexmedetomidine in anaesthesia
Current Opinion in Anaesthesiology, 2005The development of dexmedetomidine, a potent and highly selective alpha2-adrenoceptor agonist, has created new interest in the use of alpha2-adrenoceptor agonists, and has led to its evaluation in various yet non-approved perioperative settings. The current review focuses on the usefulness of dexmedetomidine in anaesthesia practice.Recently acquired ...
A. Paris, Peter H. Tonner
openaire +3 more sources
Der Anaesthesist, 2012
Dexmedetomidine is a highly selective, potent α₂-adrenoceptor agonist which was approved in 2011 by the European Medicines Agency for sedation of patients in intensive care units (ICU). Dexmedetomidine exhibits sedative as well as analgesic and anxiolytic effects.
T.I. Saari, H. Ihmsen
openaire +3 more sources
Dexmedetomidine is a highly selective, potent α₂-adrenoceptor agonist which was approved in 2011 by the European Medicines Agency for sedation of patients in intensive care units (ICU). Dexmedetomidine exhibits sedative as well as analgesic and anxiolytic effects.
T.I. Saari, H. Ihmsen
openaire +3 more sources
Journal of the American Veterinary Medical Association, 2003
Abstract Objective—To determine sedative and cardiorespiratory effects of dexmedetomidine alone and in combination with butorphanol or ketamine in cats. Design—Randomized crossover study. Animals—6 healthy adult cats. Procedures—Cats were given dexmedetomidine alone (10 μg/kg [4.5 mg/lb], IM), a combination of ...
André Luis Selmi +4 more
openaire +2 more sources
Abstract Objective—To determine sedative and cardiorespiratory effects of dexmedetomidine alone and in combination with butorphanol or ketamine in cats. Design—Randomized crossover study. Animals—6 healthy adult cats. Procedures—Cats were given dexmedetomidine alone (10 μg/kg [4.5 mg/lb], IM), a combination of ...
André Luis Selmi +4 more
openaire +2 more sources
Drugs of Today, 1999
Pharmacological manipulation of the sympathetic tone has led to the synthesis of novel compounds to control stress-induced hemodynamic disorders. The use of alpha(2)-adrenoceptor agonists is particularly interesting in this regard, since these agents decrease sympathetic activity by reducing norepinephrine release from nerve terminals.
openaire +2 more sources
Pharmacological manipulation of the sympathetic tone has led to the synthesis of novel compounds to control stress-induced hemodynamic disorders. The use of alpha(2)-adrenoceptor agonists is particularly interesting in this regard, since these agents decrease sympathetic activity by reducing norepinephrine release from nerve terminals.
openaire +2 more sources
Survey of Anesthesiology, 1993
To evaluate the effects of dexmedetomidine, an alpha-2 agonist, as an intravenous sedative drug and the effects of atipamezole, an alpha-2 antagonist, on recovery.Randomized, double-blind study with three parallel groups. An open dose-finding study preceded it to optimize the atipamezole dose.Outpatient operating room at the gynecologic and obstetric ...
Antero Kallio +9 more
openaire +3 more sources
To evaluate the effects of dexmedetomidine, an alpha-2 agonist, as an intravenous sedative drug and the effects of atipamezole, an alpha-2 antagonist, on recovery.Randomized, double-blind study with three parallel groups. An open dose-finding study preceded it to optimize the atipamezole dose.Outpatient operating room at the gynecologic and obstetric ...
Antero Kallio +9 more
openaire +3 more sources
Pharmacokinetics and pharmacodynamics of dexmedetomidine
Drug Development and Industrial Pharmacy, 2016Dexmedetomidine is an alpha-2 adrenoceptor agonist and has been used as a general anesthetic, sedative and analgesic for about 30 years. The aim of this paper is to review the pharmacokinetics and pharmacodynamics of dexmedetomidine, evaluate physiological factors that may affect the pharmacokinetics of dexmedetomidine, and summarize the ...
Kwok, PCL, Dufay, S, Yuen, VMY, LI, A
openaire +5 more sources
European Journal of Anaesthesiology, 2011
Dexmedetomidine is a potent alpha-2-adrenergic agonist, more selective than clonidine, with widespread actions on the mammalian brain that include sedation, anaesthetic-sparing, analgesia and sympatholytic properties. A large body of recent work supports its favourable profile in improving outcome and long-term brain function in the critically ill. The
Jean Mantz +2 more
openaire +3 more sources
Dexmedetomidine is a potent alpha-2-adrenergic agonist, more selective than clonidine, with widespread actions on the mammalian brain that include sedation, anaesthetic-sparing, analgesia and sympatholytic properties. A large body of recent work supports its favourable profile in improving outcome and long-term brain function in the critically ill. The
Jean Mantz +2 more
openaire +3 more sources
Dexmedetomidine pharmacokinetics in the obese
European Journal of Clinical Pharmacology, 2015This study aims to characterize the influence of body weight and composition on the pharmacokinetics of dexmedetomidine.Twenty obese patients and 20 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine infusion schemes. Venous blood samples were taken during and after dexmedetomidine administration.
Cortínez Fernández, Luis Ignacio +8 more
openaire +4 more sources
Dexmedetomidine for Neurological Surgery
Operative Neurosurgery, 2005Dexmedetomidine is a new intravenous drug gaining popularity in neuroanesthesia and neurocritical care practice. This alpha2-adrenergic receptor agonist offers a unique "cooperative sedation," anxiolysis, and analgesia with no respiratory depression.
Alex Bekker, Mary K. Sturaitis
openaire +3 more sources